Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction
暂无分享,去创建一个
C. Lacombe | P. Mayeux | D. Bouscary | F. Picard | F. Dreyfus | S. Gisselbrecht | M. Guesnu | J. Melle | M. Fontenay‐Roupie
[1] F. Gouilleux,et al. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line , 1999, Oncogene.
[2] R. Kratzke,et al. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival , 1999, Leukemia.
[3] A. Yoshimura,et al. Proteasomes Regulate Erythropoietin Receptor and Signal Transducer and Activator of Transcription 5 (STAT5) Activation , 1998, The Journal of Biological Chemistry.
[4] P. Kiener,et al. A role for tumour necrosis factor‐α, Fas and Fas‐Ligand in marrow failure associated with myelodysplastic syndrome , 1998, British journal of haematology.
[5] Michael P. Brown,et al. Stat5a and Stat5b Proteins Have Essential and Nonessential, or Redundant, Roles in Cytokine Responses , 1998, Cell.
[6] B. Mathey-Prevot,et al. Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors , 1998 .
[7] Parker,et al. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes , 1998, British journal of haematology.
[8] M. Jücker,et al. Carboxyl-Truncated STAT5β Is Generated by a Nucleus-Associated Serine Protease in Early Hematopoietic Progenitors , 1998 .
[9] J. Price,et al. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. , 1998, Blood.
[10] P. Fenaux,et al. Fas/APO-1 (CD95) expression in myelodysplastic syndromes. , 1998, Leukemia & lymphoma.
[11] B. Mathey-Prevot,et al. Interleukin-3-induced activation of the JAK/STAT pathway is prolonged by proteasome inhibitors. , 1998, Blood.
[12] K. Hirokawa,et al. Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes , 1997, Leukemia.
[13] M. Bondurant,et al. The roles of Bcl-X(L) and apopain in the control of erythropoiesis by erythropoietin. , 1997, Blood.
[14] J. D. Vos,et al. Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes , 1997, Leukemia.
[15] C. Schindler,et al. Functionally distinct isoforms of STAT5 are generated by protein processing. , 1997, Immunity.
[16] S. Burakoff,et al. Involvement of Proteasomes in Regulating Jak-STAT Pathways upon Interleukin-2 Stimulation* , 1997, The Journal of Biological Chemistry.
[17] H. Lodish,et al. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[18] A. Yoshimura,et al. STAT5 Activation Correlates with Erythropoietin Receptor-mediated Erythroid Differentiation of an Erythroleukemia Cell Line* , 1997, The Journal of Biological Chemistry.
[19] H. Lodish,et al. Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[20] L. Hoefsloot,et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. , 1997, Blood.
[21] S. Ōmura,et al. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway , 1997, Molecular and cellular biology.
[22] F. Verdier,et al. Erythropoietin‐induced erythroid differentiation of the human erythroleukemia cell line TF‐1 correlates with impaired STAT5 activation. , 1996, The EMBO journal.
[23] E. Vellenga,et al. The supportive effects of erythropoietin and mast cell growth factor on CD34+/CD36- sorted bone marrow cells of myelodysplasia patients. , 1996, Blood.
[24] U. Nir,et al. Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes. , 1996, Leukemia research.
[25] B. Groner,et al. Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. , 1996, The EMBO journal.
[26] L. Hoefsloot,et al. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand. , 1996, Leukemia.
[27] P. Greenberg,et al. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. , 1996, Blood.
[28] D Grillot,et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. , 1996, Blood.
[29] H. Mori,et al. Stepwise Movement of Preproteins in the Process of Translocation across the Cytoplasmic Membrane of Escherichia coli(*) , 1995, The Journal of Biological Chemistry.
[30] S. Ōmura,et al. Degradation Process of Ligand-stimulated Platelet-derived Growth Factor β -Receptor Involves Ubiquitin-Proteasome Proteolytic Pathway * , 1995, The Journal of Biological Chemistry.
[31] J. Krosl,et al. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin‐induced cell proliferation and Stat5 activation. , 1995, The EMBO journal.
[32] Rudolf Jaenisch,et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor , 1995, Cell.
[33] H. Preisler,et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. , 1995, Blood.
[34] N. Young,et al. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. , 1995, Blood.
[35] O. Silvennoinen,et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin , 1993, Cell.
[36] B. Löwenberg,et al. Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome. , 1992, Blood.
[37] N. Casadevall,et al. Erythropoietin induces the tyrosine phosphorylation of its own receptor in human erythropoietin-responsive cells. , 1992, The Journal of biological chemistry.
[38] M. Koury,et al. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. , 1990, Science.